Karl Rakshi

The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

Anthony G Marson, Girvan Burnside, Richard Appleton et al. · The Lancet · 2021 · 202 citations · Full text

The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

Anthony G Marson, Girvan Burnside, Richard Appleton et al. · The Lancet · 2021 · 183 citations · Full text

Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial

Finbar O’Callaghan, Stuart W. Edwards, Fabienne Dietrich Alber et al. · The Lancet Child & Adolescent Health · 2018 · 161 citations · Full text

Pain Disorders, Hormonal Treatment, Pediatrics +6

Clinical features of childhood‐onset paroxysmal kinesigenic dyskinesia with <scp><i>PRRT</i></scp><i>2</i> gene mutations

Laura Silveira‐Moriyama, A. Gardiner, Esther Meyer et al. · Developmental Medicine & Child Neurology · 2013 · 49 citations · Full text

Trials of the bronchodilator activity of the isoenzyme‐selective phosphodiesterase inhibitor AH 21‐132 in healthy volunteers during a methacholine challenge test.

RW Foster, Karl Rakshi, John R. Carpenter et al. · British Journal of Clinical Pharmacology · 1992 · 46 citations · Full text